Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 12/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801391 | 1.00 | SENP8 (0.52) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL29801796 | 0.89 | SENP7 (0.48) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL19859241 | 0.89 | SENP7 (0.48) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL19859149 | 0.89 | SENP7 (0.44) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL29801683 | 0.89 | SENP7 (0.44) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL23362519 | 0.88 | STING1 (0.43) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL29801442 | 0.88 | STING1 (0.43) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL21074334 | 0.88 | STING1 (0.43) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL21074378 | 0.88 | STING1 (0.43) | SENP8SENP7SENP6PRKCBMAPT | |
| SCHEMBL21048265 | 0.88 | MIF (0.42) | SENP8SENP7SENP6PRKCBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498277-B1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP (KR) | 2021-10-06 | — | — | EP | claimed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3498277-B1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP (KR) | 2021-10-06 | — | — | EP | disclosed |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP. (KR) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | PRKAB1, PRKAB2, PRKAG1 | SENP8 1309/4885SENP7 1041/4885SENP6 1528/4885 |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | PRKAG1, PRKAB1, PRKAG2 | SENP8 3214/4885SENP7 2506/4885SENP6 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.